XBiotech (XBIT) Non-Current Assets (2014 - 2026)
XBiotech (XBIT) posted quarterly Non-Current Assets of $23.1 million for Q4 2025, down 5.7% year-over-year from $24.5 million in Q4 2024, and down 1.47% quarter-over-quarter from $23.5 million in Q3 2025.
XBiotech (XBIT) Non-Current Assets (2014 - 2026) Analysis & Trends
XBiotech's Non-Current Assets history runs 12 years deep, the most recent figure standing at $23.1 million for Q4 2025.
- In Q4 2025, Non-Current Assets fell 5.7% year-over-year to $23.1 million; the TTM figure through Dec 2025 stood at $94.6 million (down 4.53% YoY), while the FY2025 annual figure was $23.1 million, down 5.7% from the prior year.
- Non-Current Assets for Q4 2025 stood at $23.1 million, down from $23.5 million in the prior quarter.
- The five-year high for Non-Current Assets was $29.3 million in Q3 2021, with the low at $23.1 million in Q4 2025.
- The 5-year median for Non-Current Assets is $25.4 million (2023), against an average of $26.0 million.
- Peak annual rise in Non-Current Assets reached 1.57% in 2021, while the deepest fall reached 72.09% in 2021.
- XBiotech's Non-Current Assets stood at $28.3 million in 2021, then retreated by 7.23% to $26.3 million in 2022, then declined by 5.19% to $24.9 million in 2023, then slipped by 1.49% to $24.5 million in 2024, then slipped by 5.7% to $23.1 million in 2025.
- Business Quant data shows XBIT's Non-Current Assets at $23.1 million in Q4 2025, $23.5 million in Q3 2025, and $23.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | XBiotech | 68.90 Mn | 68.90 Mn | - | 22.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.49 Mn |
| Dec 31, 2025 | 23.13 Mn |
| Sep 30, 2025 | 23.47 Mn |
| Jun 30, 2025 | 23.79 Mn |
| Mar 31, 2025 | 24.18 Mn |
| Dec 31, 2024 | 24.53 Mn |
| Sep 30, 2024 | 24.82 Mn |
| Jun 30, 2024 | 24.92 Mn |
| Mar 31, 2024 | 24.80 Mn |
| Dec 31, 2023 | 24.90 Mn |
| Sep 30, 2023 | 25.20 Mn |
| Jun 30, 2023 | 25.62 Mn |
| Mar 31, 2023 | 25.84 Mn |
| Dec 31, 2022 | 26.26 Mn |
| Sep 30, 2022 | 27.41 Mn |
| Jun 30, 2022 | 27.70 Mn |
| Mar 31, 2022 | 27.82 Mn |
| Dec 31, 2021 | 28.31 Mn |
| Sep 30, 2021 | 29.28 Mn |
| Jun 30, 2021 | 29.09 Mn |